Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab rollover safety study for participants benefiting after prior anifrolumab trial
NL-OMON61754Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anifrolumab in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), cutaneous lupus erythematosus (CLE) and 1 more, sponsored by AstraZeneca. Primary endpoint: Safety. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)cutaneous lupus erythematosus (CLE)myopathies
Beyond the preview
Go deeper on NL-OMON61754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61754.